Efficacy and Safety of Oral Immunotherapy With GcMAF in Hospitalized Patients With COVID-19 Pneumonia

PHASE2CompletedINTERVENTIONAL
Enrollment

97

Participants

Timeline

Start Date

November 5, 2020

Primary Completion Date

April 30, 2021

Study Completion Date

June 30, 2021

Conditions
COVID-19 Pneumonia
Interventions
DIETARY_SUPPLEMENT

Saisei Maf capsules

Dietary supplement name: Colostrum MAF, Saisei MAF immunomodulator. Formulation: 148 mg acid-resistant coated capsules, containing 2.3 mg of enzymatically treated bovine colostrum powder and supplementary ingredients The dietary supplement substances: Active ingredien: Enzymatically treated bovine colostrum powder 2.3 mg 1.6 % Supplementary ingredients: Lactase (Derived from yeast) 0,15 mg 0.1 % HPMC (Hydroxypropyl Methylcellulose) acid-resistant capsule 47 mg 31.8 % Microcrystalline cellulose (Derived from pulp) 98,4 mg 66.5 % Dosage for adults: 2 - 10 capsules daily (stronger version 9 capsules daily) Route of administration: oral Contraindication: allergy to dairy product components Precaution: pregnancy and lactation Storage: Can be stored in at + 5 to +25°C, on dry place for up to two years Manufacturer: Saisei Pharma, Osaka, MORIGUCHI city, OKUBO-cho, 3-34-8. Japan

Trial Locations (1)

80131

Ospedale del Mare Hospital, Naples

All Listed Sponsors
lead

Dr. Spadera Lucrezia

OTHER

NCT04845971 - Efficacy and Safety of Oral Immunotherapy With GcMAF in Hospitalized Patients With COVID-19 Pneumonia | Biotech Hunter | Biotech Hunter